SG11201902523UA - Anti-proliferative agents for treating pah - Google Patents
Anti-proliferative agents for treating pahInfo
- Publication number
- SG11201902523UA SG11201902523UA SG11201902523UA SG11201902523UA SG11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new york
- pct
- applicant
- rule
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 108010081589 Becaplermin Proteins 0.000 abstract 1
- 101150012716 CDK1 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004390 palbociclib Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410566P | 2016-10-20 | 2016-10-20 | |
| US201762548629P | 2017-08-22 | 2017-08-22 | |
| PCT/IB2017/056226 WO2018073687A1 (en) | 2016-10-20 | 2017-10-09 | Anti-proliferative agents for treating pah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902523UA true SG11201902523UA (en) | 2019-05-30 |
Family
ID=60138667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902523UA SG11201902523UA (en) | 2016-10-20 | 2017-10-09 | Anti-proliferative agents for treating pah |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10849903B2 (es) |
| EP (2) | EP3804724B1 (es) |
| JP (2) | JP2018076290A (es) |
| KR (1) | KR20190071763A (es) |
| CN (1) | CN109843297A (es) |
| AU (1) | AU2017345367A1 (es) |
| BR (1) | BR112019005526A2 (es) |
| CA (1) | CA3040815C (es) |
| ES (2) | ES2934846T3 (es) |
| IL (1) | IL266026A (es) |
| MX (1) | MX2019004602A (es) |
| RU (1) | RU2019111887A (es) |
| SG (1) | SG11201902523UA (es) |
| TW (1) | TWI656876B (es) |
| WO (1) | WO2018073687A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111533XA (en) * | 2019-04-19 | 2021-11-29 | Pfizer | Anti-proliferative agents for treating pah |
| TWI769382B (zh) * | 2019-06-21 | 2022-07-01 | 長庚大學 | 利博西林用於製備治療罹患磷酸二酯酶４介導疾病的患者的醫藥組合物及用途 |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| EP1280789A1 (en) | 2000-05-03 | 2003-02-05 | LG Life Sciences Ltd. | Cdk inhibitors having 3-hydroxychromen-4-one structure |
| DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| CN1835951B (zh) | 2003-07-11 | 2010-06-02 | 沃尼尔·朗伯有限责任公司 | 选择性cdk4抑制剂的羟乙基磺酸盐 |
| US7947695B2 (en) | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| KR20090052385A (ko) | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성 |
| JP5407865B2 (ja) * | 2006-11-23 | 2014-02-05 | ジノクサ ファルマ ゲーエムベーハー | 毛細管動脈疾患治療用医薬組成物 |
| SI2212297T1 (sl) * | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
| EP2279267A4 (en) * | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES |
| WO2010000913A1 (en) | 2008-07-04 | 2010-01-07 | Lauri Ilmari Pekansaari | Sauna oven center boiler |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| KR101353857B1 (ko) | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| CA2771563A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
| IN2012DN01273A (es) | 2009-09-04 | 2015-05-15 | Novartis Ag | |
| WO2011083387A1 (en) * | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CA2961937C (en) | 2010-10-25 | 2018-09-25 | G1 Therapeutics, Inc. | Cdk inhibitors |
| WO2012066508A1 (en) | 2010-11-19 | 2012-05-24 | Piramal Life Sciences Limited | Pharmaceutical combination of paclitaxel and a cdk inhibitor |
| KR20150107872A (ko) | 2013-02-21 | 2015-09-23 | 화이자 인코포레이티드 | 고체 형태의 선택적인 cdk4/6 억제제 |
| AP2016009483A0 (en) | 2014-04-11 | 2016-10-31 | Bayer Pharma AG | Novel macrocyclic compounds |
| CN105294655B (zh) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| WO2016015597A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| WO2016053040A1 (ko) | 2014-10-02 | 2016-04-07 | 주식회사 엘지화학 | 리튬 이차 전지용 전해액 첨가제, 상기 전해액 첨가제를 포함하는 비수성 전해액 및 리튬 이차 전지 |
| CN104758292B (zh) * | 2015-03-06 | 2018-05-01 | 天津医科大学总医院 | Pd-0332991在制备防治耐药肿瘤药物的用途 |
| WO2016160881A1 (en) * | 2015-04-01 | 2016-10-06 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
-
2017
- 2017-10-09 CA CA3040815A patent/CA3040815C/en active Active
- 2017-10-09 ES ES20203847T patent/ES2934846T3/es active Active
- 2017-10-09 BR BR112019005526A patent/BR112019005526A2/pt not_active Application Discontinuation
- 2017-10-09 KR KR1020197014211A patent/KR20190071763A/ko not_active Application Discontinuation
- 2017-10-09 CN CN201780064690.9A patent/CN109843297A/zh active Pending
- 2017-10-09 US US16/343,566 patent/US10849903B2/en active Active
- 2017-10-09 WO PCT/IB2017/056226 patent/WO2018073687A1/en unknown
- 2017-10-09 ES ES17787029T patent/ES2852349T3/es active Active
- 2017-10-09 RU RU2019111887A patent/RU2019111887A/ru not_active Application Discontinuation
- 2017-10-09 SG SG11201902523UA patent/SG11201902523UA/en unknown
- 2017-10-09 AU AU2017345367A patent/AU2017345367A1/en not_active Abandoned
- 2017-10-09 MX MX2019004602A patent/MX2019004602A/es unknown
- 2017-10-09 EP EP20203847.7A patent/EP3804724B1/en active Active
- 2017-10-09 EP EP17787029.2A patent/EP3528812B1/en active Active
- 2017-10-17 TW TW106135422A patent/TWI656876B/zh not_active IP Right Cessation
- 2017-10-18 JP JP2017201576A patent/JP2018076290A/ja active Pending
-
2019
- 2019-04-14 IL IL266026A patent/IL266026A/en unknown
-
2020
- 2020-11-04 US US17/089,154 patent/US11439646B2/en active Active
- 2020-12-01 JP JP2020199659A patent/JP2021038265A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019111887A3 (es) | 2020-11-20 |
| US11439646B2 (en) | 2022-09-13 |
| ES2852349T3 (es) | 2021-09-13 |
| CA3040815A1 (en) | 2018-04-26 |
| MX2019004602A (es) | 2019-06-17 |
| US20210186974A1 (en) | 2021-06-24 |
| RU2019111887A (ru) | 2020-11-20 |
| CN109843297A (zh) | 2019-06-04 |
| EP3528812B1 (en) | 2020-12-30 |
| EP3804724B1 (en) | 2022-12-07 |
| EP3804724A1 (en) | 2021-04-14 |
| TW201827054A (zh) | 2018-08-01 |
| US10849903B2 (en) | 2020-12-01 |
| AU2017345367A1 (en) | 2019-04-04 |
| KR20190071763A (ko) | 2019-06-24 |
| EP3528812A1 (en) | 2019-08-28 |
| WO2018073687A1 (en) | 2018-04-26 |
| IL266026A (en) | 2019-06-30 |
| CA3040815C (en) | 2021-07-20 |
| BR112019005526A2 (pt) | 2019-06-18 |
| JP2021038265A (ja) | 2021-03-11 |
| US20190240226A1 (en) | 2019-08-08 |
| JP2018076290A (ja) | 2018-05-17 |
| TWI656876B (zh) | 2019-04-21 |
| ES2934846T3 (es) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |